Your search for supplemental oxygen returned 87 results

Authors call for larger clinical trials to further evaluate the efficacy and safety of colchicine as an adjunctive therapy for COVID-19

Routine use of supplemental oxygen does not reduce one-year all-cause mortality versus ambient air

Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients.

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.

The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.

The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.

Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.

Currently, there are no approved treatments for COVID-19, however, several investigational therapies are in the works.

The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.

Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.